Core Points - Ekso Bionics Holdings, Inc. has entered into a definitive agreement for the purchase and sale of 769,490 shares of common stock at a price of $4.81 per share, expected to close around October 30, 2025 [1] - The gross proceeds from this offering are anticipated to be $3.7 million, which will be used for general corporate purposes including research and development, administrative costs, and working capital needs [3] - The shares are being offered under a "shelf" registration statement previously filed with the SEC, and the offering will be conducted via a prospectus [4] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility for both medical and industrial applications [6] - The company focuses on improving health and quality of life through advanced robotics, and is recognized for its unique technologies that assist individuals with paralysis and enhance capabilities in various job sites [6] - Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [6]

Core Viewpoint - China Harbour International Financial Limited successfully assisted SIGUWORKS in the tokenization and issuance of real world assets (RWA) for its IP brand Puff Koala, marking a significant development in the digital finance sector [1][3]. Group 1: Project Overview - The RWA issuance project is designed around KOALA's IP licensing income rights in Southeast Asia, North America, and Europe, utilizing blockchain technology for tokenization [3]. - The total size of the issuance is in the tens of millions of US dollars, making it the largest IP RWA project in recent times [4]. - The project employs an offshore special purpose vehicle (SPV) structure, with cash flow from underlying assets distributed to token holders via smart contracts, ensuring transparency and automation in profit distribution [4]. Group 2: Company Expertise - China Harbour International specializes in digital financial investment banking and holds multiple licenses from the Securities and Futures Commission of Hong Kong, enabling various financial services [5]. - The company offers comprehensive services in RWA issuance, including asset screening, structural design, legal compliance, and technical implementation, while maintaining close cooperation with leading industry institutions [5]. - China Harbour International has a deep understanding of global regulatory requirements, allowing it to design optimal cross-border issuance solutions for clients [5]. Group 3: Technical Capabilities - The company has developed an asset chain platform with independent intellectual property rights to ensure the authenticity and integrity of underlying asset data [6]. - The platform utilizes IoT devices to collect real-time asset operation data, providing investors with a transparent asset monitoring experience [6].

Core Insights - Purple Biotech has achieved a commercially viable yield for IM1240, a tri-specific antibody targeting the tumor-associated antigen 5T4, positioning the program competitively for future development [1] - The CAPTN-3 platform has been validated for scalability, indicating its potential for developing complex tri-specific antibodies with competitive yield and purity [2] Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance, with a pipeline that includes CAPTN-3, CM24, and NT219 [3] - IM1240 is the first tri-specific antibody in development targeting the 5T4 antigen, which is associated with advanced disease and poor clinical outcomes in various solid tumors [3] Technology and Mechanism - The CAPTN-3 platform generates conditionally activated tri-specific antibodies that engage both T cells and NK cells, inducing a strong localized immune response within the tumor microenvironment [2][3] - The technology incorporates a cleavable capping mechanism that confines therapeutic activity to the tumor microenvironment, potentially increasing the therapeutic window for patients [2][3] Clinical Development - An Investigational New Drug (IND) submission for IM1240 is planned for 2026, with the antibody advancing toward first-in-human clinical trials [1] - NT219 has demonstrated anti-tumor activity in combination with cetuximab in a Phase 1 study and is currently being evaluated in a Phase 2 study for recurrent and/or metastatic squamous cell carcinoma of the head and neck [4]

Strong Balance Sheet and Market-Leading Technologies Enable Continued Investments in GrowthMIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Watsco, Inc. (NYSE: WSO) announced its operating results for the third quarter and nine-month period ended September 30, 2025. The Company also provided updates related to innovation and technology, business trends and long-term growth opportunities. Watsco is the largest distributor in the highly-fragmented $74 billion North American market for HVAC products. Since entering di ...

Results Highlighted by Solid Loan and Deposit GrowthLOUISVILLE, Ky., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank & Trust Company, with offices in Louisville, central, eastern and northern Kentucky, as well as the Indianapolis, Indiana and Cincinnati, Ohio metropolitan markets, today reported record earnings of $36.2 million, or $1.23 per diluted share, for the third quarter ended September 30, 2025. This compares to net income of $29.4 milli ...

Core Insights - Medicus Pharma Ltd. has announced a strategic collaboration with the Gorlin Syndrome Alliance to enhance access to its investigational therapy SKINJECT™ for patients with Gorlin Syndrome, a rare genetic disorder that can lead to numerous basal cell carcinomas [1][2][5] Company Overview - Medicus Pharma Ltd. is a biotech/life sciences company focused on advancing clinical development programs for novel therapeutics [1][9] - The company is currently conducting a Phase 2 clinical study (SKNJCT-003) for SKINJECT™ across nine clinical sites in the United States, which began randomizing patients in August 2024 [5][10] - Medicus has also expanded its clinical studies to Europe and is conducting another study (SKNJCT-004) in the UAE, targeting a total of 36 patients [6][10] Product Development - SKINJECT™ is an investigational localized immunogenic therapy aimed at treating non-melanoma skin diseases, particularly basal cell carcinoma [3][10] - The Phase 2 study (SKNJCT-003) has shown promising interim results, with over 60% clinical clearance reported after randomizing more than 50% of the targeted 60 patients [5][10] - The FDA has provided positive feedback regarding the development of SKINJECT™, indicating a potential 505(b)(2) regulatory pathway for its approval [5][10] Collaboration and Community Engagement - The collaboration with the Gorlin Syndrome Alliance aims to facilitate expanded access to SKINJECT™ while integrating patient community insights into the treatment's development [2][5] - The Gorlin Syndrome Alliance serves as a bridge between patients, clinicians, researchers, and industry, promoting awareness and providing support for those affected by Gorlin Syndrome [18][19] Recent Acquisitions - In August 2025, Medicus completed the acquisition of Antev, a UK-based biotech company developing Teverelix, a next-generation GnRH antagonist for advanced prostate cancer patients [7][12] - Teverelix is designed to suppress sex hormone production without an initial surge, potentially reducing cardiovascular risks for patients with existing conditions [8][13]

Core Insights - Anavex Life Sciences Corp. announced new findings for blarcamesine, an oral small molecule for the potential treatment of early Alzheimer's disease, demonstrating significant cognitive benefits compared to the ADNI control group [1][2][5] Group 1: Clinical Trial Results - In the intent-to-treat population, blarcamesine showed a significant reduction in cognitive decline at 48 weeks with a mean change from baseline ADAS-Cog13 total score of -2.68 points (p < 0.0001) compared to the ADNI control group [4] - At 96 weeks, the difference in mean change in ADAS-Cog13 total score was -6.41 points (p < 0.0001), and this difference increased to -12.78 points at 144 weeks (p < 0.0001) [5][7] - The treatment resulted in 77.4 weeks (approximately 17.8 months) of 'time saved' in the ITT population compared to the ADNI control group, emphasizing the real-world impact of the treatment on patients' daily lives [9][10] Group 2: Mechanism of Action - Blarcamesine was confirmed to restore impaired autophagy, acting upstream of amyloid-beta and tau pathologies, which are critical in Alzheimer's disease progression [11][12] - The mechanism involves SIGMAR1 activation, enhancing autophagic flux and proteostasis capacity, which may ameliorate symptoms associated with protein aggregation [12] Group 3: Company Perspective - The company expressed optimism about the significant clinical improvements and the favorable safety profile of blarcamesine, highlighting its potential as a scalable and patient-friendly treatment option for early Alzheimer's disease [13] - Anavex plans to present this new data at international Alzheimer's disease conferences, aiming to advance treatment strategies for this chronic condition [13]

CHICAGO and MINNEAPOLIS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo”) (CSE: VREO; OTCQX: VREOF) and Verano Holdings Corp. (“Verano”, Vireo and Verano, each a “Company”) (Cboe CA: VRNO) (OTCQX: VRNOF) today announced that they have reached a comprehensive settlement (the “Settlement Agreement”) dismissing all outstanding litigation matters between the two Companies that are pending before the Supreme Court of British Columbia, Canada. The terms of the Settlement Agreement were approved by th ...

Core Insights - Southern Michigan Bancorp, Inc. reported a net income of $3,019,000 for Q3 2025, representing a 16.70% increase from $2,586,000 in Q3 2024 [1] - For the first nine months of 2025, net income reached $9,303,000, a 20.0% increase compared to $7,751,000 in the same period of 2024 [1] Financial Performance - The annualized return on average assets improved to 0.79% for the nine months ended September 30, 2025, up from 0.70% for the same period in 2024 [2] - The annualized return on average equity increased to 11.00% in the first nine months of 2025, compared to 10.18% in the first nine months of 2024 [2] - The tax equivalent net interest margin rose to 3.21% for the nine-month period ending September 30, 2025, compared to 2.94% for the same period in 2024 [2] Operational Highlights - The company achieved record levels in loans, deposits, and total assets by the end of the quarter, as stated by the CEO [3] - The allowance for credit losses was $14,410,000, or 1.17% of loans, as of September 30, 2025 [3] - Non-performing loans as a percentage of total loans increased to 1.03% as of September 30, 2025, from 0.08% as of December 31, 2024 [3] Balance Sheet Overview - Total assets reached $1,665,097,000 as of September 30, 2025, compared to $1,496,555,000 as of December 31, 2024 [6][7] - Total deposits increased to $1,394,932,000 in September 2025, up from $1,251,795,000 in December 2024 [7] - Shareholders' equity rose to $117,778,000 as of September 30, 2025, compared to $107,223,000 at the end of 2024 [7] Income Statement Summary - Total interest income for Q3 2025 was $21,269,000, compared to $19,531,000 in Q3 2024 [8][9] - Net interest income after provision for credit losses was $10,886,000 for Q3 2025, up from $9,968,000 in Q3 2024 [9] - Non-interest income totaled $2,618,000 for Q3 2025, compared to $2,172,000 in Q3 2024 [9]

The intersection of Blue Gold’s strategy with global adoption of blockchain technology and responsible regulation, a renewed focus on gold as a store of value, and a growing demand for real assets as credible alternatives to fiat currenciesNEW YORK, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Blue Gold Limited (Nasdaq: BGL) ("Blue Gold" or the “Company”), a next-generation gold development and technology company, sets out its vision, mission and strategy to become a market leading vertically integrated gold compa ...